10.12.2012 Views

netLibrary - eBook Summary Structure-based Drug Design by ...

netLibrary - eBook Summary Structure-based Drug Design by ...

netLibrary - eBook Summary Structure-based Drug Design by ...

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

Document<br />

Page 313<br />

residues that have been the main focus of attention hitherto. A key requirement now is to identify those<br />

residues that provide the majority of the binding energy and to differentiate these from others whose<br />

main role is to stabilize the binding residues in the active conformation.<br />

VII. Mimicking The Pharmacophore<br />

Significant progress has been made over the past few years in the field of peptide mimetics, although the<br />

most successful examples are those where a small peptide ligand or a linear segment of a larger protein<br />

has been the target [72–74]. An alternative approach to de novo design is to optimize a lead compound<br />

obtained <strong>by</strong> screening chemical libraries on the basis of a knowledge of the conformation of the<br />

polypeptide ligand, as in the case of the endothelin receptor antagonist SB 209670 [75].<br />

The task of mimicking a pharmacophore is simplified where the contributing residues are contiguous in<br />

the amino acid sequence. This is not the case in the anthopleurins, with residues from at least four<br />

different regions of the sequence contributing to affinity. In charybdotoxin the essential residues come<br />

from two or three regions of the sequence, depending on which potassium channel is considered, while<br />

in growth hormone, binding site I is comprised of residues from three different regions of the protein<br />

and site II from two regions. Mimicking the pharmacophore of the anthopleurins therefore represents a<br />

task at least as challenging as those presented <strong>by</strong> these two examples. Strategies for achieving this goal<br />

include de novo design, conformationally directed data base searching and screening chemical libraries<br />

(synthetic and naturally occurring) for leads, which could then be optimized on the basis of our<br />

knowledge of the structure. Our approach is <strong>based</strong> on the first two of these.<br />

Initial attempts to mimic the pharmacophore of AP-A were <strong>based</strong> on linear and disulfide-cyclized<br />

versions of the Arg14-containing loop [76]. At that time, our level of understanding of the<br />

pharmacophore was inadequate and it is clear in retrospect that not enough of the key elements were<br />

present. Nevertheless, conformational analysis of these peptides <strong>by</strong> NMR was useful in showing that<br />

they retained several elements of local structure observed in the corresponding region of the native<br />

protein, there<strong>by</strong> emphasizing the independence of this loop from the rest of the structure in solution.<br />

VIII. Conclusions<br />

In this chapter I have attempted to summarize the current state of our understanding of the structure and<br />

structure-function relationships of the type 1 sea<br />

http://legacy.netlibrary.com/nlreader/nlReader.dll?bookid=12640&filename=Page_313.html [4/5/2004 5:24:04 PM]

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!